Mac Plus Capsule SR contains a combination of Levosulpiride 75 mg and Rabeprazole 20 mg, formulated to manage gastrointestinal disorders associated with dysmotility and acid-related conditions. Levosulpiride, a selective dopamine D2 receptor antagonist, facilitates gastric motility by enhancing gastric emptying and improving esophageal sphincter tone, thereby alleviating symptoms such as nausea, vomiting, bloating, and abdominal discomfort. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related disorders including gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The sustained-release formulation ensures prolonged therapeutic effects, optimizing symptom control and improving patient compliance. Mac Plus Capsule SR is indicated for the treatment of functional dyspepsia, gastroesophageal reflux disease, and other acid-peptic disorders where impaired motility and acid hypersecretion coexist. It should be administered under medical supervision, with dosage adjustments based on clinical response. Caution is advised in patients with hypersensitivity to either component, severe hepatic or renal impairment, and during pregnancy or lactation. Adverse effects may include headache, dizziness, diarrhea, or hypersensitivity reactions. Regular monitoring is recommended to ensure efficacy and safety during therapy.